Scarica l'app Stockscreener
593.25
0.76%
-4.53
Dopo l'orario di chiusura:
592.00
-1.25
-0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$597.78
Aprire:
$593.43
Volume 24 ore:
2.06M
Relative Volume:
1.03
Capitalizzazione di mercato:
$222.89B
Reddito:
$43.74B
Utile/perdita netta:
$6.58B
Rapporto P/E:
34.28
EPS:
17.3072
Flusso di cassa netto:
$6.11B
1 W Prestazione:
+3.39%
1M Prestazione:
+3.62%
6M Prestazione:
+50.70%
1 anno Prestazione:
+15.65%
Intervallo 1D:
$587.18
$596.55
Intervallo di 1 settimana:
$568.46
$602.32
Portata 52W:
$385.46
$610.97
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Confronta TMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
593.25 | 224.59B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.46 | 163.00B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
755.96 | 61.22B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
154.37 | 44.50B | 6.95B | 1.30B | 1.09B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
231.80 | 39.50B | 15.90B | 1.28B | 2.21B | 7.2842 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Is the Market Bullish or Bearish on Thermo Fisher Scientific Inc? - Benzinga
Laboratory Informatics Market- By Type Thermo Fisher - openPR.com
Thermo Fisher executive Shafer sells $6.43 million in stock By Investing.com - Investing.com India
Price Over Earnings Overview: Thermo Fisher Scientific - Benzinga
Cell Culture Collagen Market to Attain USD 4.19 Billion by 2034, Driven by Expanding Healthcare Applications - GlobeNewswire Inc.
US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad - GlobeNewswire
Thermo Fisher Scientific Stock: Is TMO Outperforming the Health Care Sector? - Yahoo Finance
Thermo Fisher launches bioprocess design centre in Hyd - The Hans India
Thermo Fisher Inaugurates Customer Experience and Bioprocess Centre’s in Hyderabad - Chemical Industry Digest
Medical Precision Parts Market Research Report 2025-2030 Featuring Key PlayersGemsons, ARC, Precision Resource, Thermo Fisher Scientific, Stryker, Linamar, and TS PrototypesResearchAndMarkets.com - Business Wire
Thermo Fisher Scientific prices offering of senior notes - Medical Buyer
Competent Cells Market to Get an Explosive Growth| Thermo Fisher - openPR.com
Gene Silencing Market Is Booming Worldwide 2025-2032 | Thermo - openPR.com
Cell Culture Media Market Growing Trends and Demands Analysis - openPR.com
Thermo Fisher expands India footprint with Customer Experience, Bioprocess Design Centers at Genome... - Medical Dialogues
Thermo Fisher Scientific Prices Offering of Euro-Denominated Notes at 100% of Par Value - MarketScreener
Thermo Fisher Scientific prices €2.1B euro-denominated senior notes offering - MSN
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes - BioSpace
Are Thermo Fisher Shares a Fair Deal After Key Pharma Partnerships and 14% Price Surge? - Yahoo Finance
Thermo Fisher prices €2.1 billion notes offering in two tranches - Investing.com
Thermo Fisher prices €2.1 billion notes offering in two tranches By Investing.com - Investing.com Australia
Thermo Fisher Scientific Subsidiary Prices EUR 2.1 Bln Senior Notes Offering - Nasdaq
Thermo Fisher Scientific prices 2.1 billion euros euro-denominated notes offering - MarketScreener
Thermo Fisher (NYSE: TMO) Prices €2.1B Euro Senior and Floating-Rate Notes - Stock Titan
Thermo Fisher opens CGT collaboration center in Philadelphia - BioProcess International
Thermo Fisher launches TSQ Certis triple quadrupole mass spectrometer - rdworldonline.com
Thermo Fisher goes big with first euro bond since 2022 - GlobalCapital
Thermo Fisher Scientific sets up 2 facilities in Hyd - BusinessLine
Fitch Rates Thermo Fisher Scientific (Finance I) B.V.'s Senior Euro Notes 'A-' - TradingView
Research Antibodies Market Size, Outlook 2030 by Key Companies- - openPR.com
Thermo Fisher (NYSE:TMO) Shares Edge Higher on Sector Activity - Kalkine Media
Thermo Fisher Scientific (TMO): Assessing Valuation After FDA Wins Expand Cancer and Diagnostic Offerings - simplywall.st
Thermo Fisher Scientific Stock Prediction: Where Analysts See the Stock Going by 2027 - TIKR.com
Why Is Thermo Fisher (TMO) Up 0.2% Since Last Earnings Report? - sharewise.com
Thermo Fisher Scientific Launches Industry-First, Multi-Parameter Molecular Assay for Rapid Beverage Quality Testing* - Food Industry Executive
Genomic Biomarker Market By Top Companies Illumina,Thermo - openPR.com
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - BioSpace
Thermo Fisher Scientific: Assessing Value After Diagnostics Acquisition and Recent Share Price Gains - simplywall.st
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth - The Globe and Mail
TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner - TradingView
Thermo Fisher Expands U.S. Cell & Gene Therapy Network with New Advanced Therapies Center in Philadelphia - Voice Of HealthCare
Can Thermo Fisher Scientific Inc. stock sustain institutional interestMarket Risk Analysis & Short-Term High Return Ideas - newser.com
The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following EXENT System Clearance and New Philly Center Opening – Learn Why - Yahoo Finance
Will Thermo Fisher Scientific Inc stock outperform benchmarksSell Signal & Safe Entry Point Identification - newser.com
Will Thermo Fisher Scientific Inc. (TN8) stock sustain bullish trend into 2025Market Trend Report & Consistent Income Trade Ideas - newser.com
Is Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock good for long term investingJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
How Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock behaves in tightening cyclesTrade Exit Summary & Safe Entry Zone Identification - newser.com
Institutions Love These 3 Companies, Should You As Well? - Finviz
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two - PharmTech.com
Will Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock hit analyst forecastsTrade Entry Report & Fast Moving Trade Plans - newser.com
Thermo Fisher unveils Advanced Therapies Collaboration Centre in US - BioSpectrum Asia
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.00%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):